¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Interferon-Stimulated Gene Factor 3, alpha Subunit"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • gene regulation
    À¯ÀüÀÚÁ¶Àý
  • gene replacement
    À¯ÀüÀÚ±³È¯
  • gene segment
    À¯ÀüÀÚÁ¶°¢
  • gene splicing
    À¯ÀüÀÚ½ºÇöóÀ̽Ì, À¯ÀüÀÚÀß¶óÀÌÀ½
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
  • gene transfection
    1. À¯ÀüÀÚÀü´Þ°¨¿° 2. À¯ÀüÀÚÇÙ³»ÁÖÀÔ
  • gene transfer
    À¯ÀüÀÚÀü´Þ
  • gene transfer therapy
    À¯ÀüÀÚÀ̽Ŀä¹ý
  • gene translocation
    À¯ÀüÀÚÀÚ¸®¿Å±è, À¯ÀüÀÚÀüÀ§
  • gonosomal gene
    ¼º¿°»öüÀ¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ÀûÇÕÇ׿øÀ¯ÀüÀÚ
  • hox gene
    Ȥ½ºÀ¯ÀüÀÚ
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • hox gene
    Ȥ½ºÀ¯ÀüÀÚ
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ
  • major histocompatibility gene
    ÁÖÁ¶Á÷ÀûÇÕ¼ºÀ¯ÀüÀÚ
  • marker gene
    Ç¥ÁöÀ¯ÀüÀÚ
  • modulator gene
    ÀÛµ¿À¯ÀüÀÚ, ¸Å°³À¯ÀüÀÚ
  • molecular check point gene
    ºÐÀڰ˹®À¯ÀüÀÚ
  • mutant gene
    µ¹¿¬º¯ÀÌÀ¯ÀüÀÚ
  • mutator gene
    º¯ÀÌÀ¯¹ßÀ¯ÀüÀÚ
  • nucleolar gene
    ÇÙ¼ÒüÀ¯ÀüÀÚ
  • operator gene
    ÀÛµ¿À¯ÀüÀÚ
  • recessive gene
    ¿­¼ºÀ¯ÀüÀÚ
  • regulator gene
    Á¶ÀýÀ¯ÀüÀÚ
  • reporter gene
    Á¤º¸Á¦°øÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • rb gene
    Rb À¯ÀüÀÚ(¡­ë¶îîí­)
  • recessive autosomal gene
    ¿­¼ºº¸Åë¿°»öüÀ¯ÀüÀÚ
  • recessive gene
    ¿­¼ºÀ¯ÀüÀÚ(¡­ë¶îîí­).
  • recessive gene
    ¿­¼ºÀ¯ÀüÀÚ
  • recessive gonosomal gene
    ¿­¼º¼º¿°»öüÀ¯ÀüÀÚ
  • recombination, gene
    À¯ÀüÀÚÀçÁ¶ÇÕ
  • regulator gene
    Á¶ÀýÀ¯ÀüÀÚ(ðàï½ë¶îîí­).
  • 17-alpha-hydroxycorticosteroid
    17-¾ËÆÄ-È÷µå·Ï½ÃÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
  • 17-alpha-hydroxyprogesterone
    17-¾ËÆÄ-È÷µå·Ï½ÃÇÁ·Î°Ô½ºÅ×·Ð
  • alpha behavior
    ¾ËÆÄÇàÀ§
  • alpha blocking
    ¾ËÆÄÂ÷´Ü
  • alpha cell
    ¾ËÆÄ¼¼Æ÷
  • alpha cell
    ¾ËÆÄ¼¼Æ÷(¡­á¬øà)
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • alpha cell tumor
    ¾ËÆÄ ¼¼Æ÷Á¾(¡­á¬øàðþ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸°¼ö¿ëü.
  • alpha-adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³¯¸°¼ö¿ëü
  • alpha-amino acid nitrogen
    ¾ËÆÄ-¾Æ¹Ì³ë»êÁú¼Ò
  • alpha-chain disease
    ¾ËÆÄ¼â Áúȯ(¡­áð òðü´)
  • alpha-chymotrypsin
    ¾ËÆÄÄ«ÀÌ¸ðÆ®¸³½Å
  • alpha-fetoprotein
    ¾ËÆÄžƴܹé
  • alpha-fetoprotein
    ¾ËÆÄ-žƴܹé(¡­÷Ãä®Ó±ÛÜ)
  • alpha-fucosidase
    ¾ËÆÄ-ǪÄڽôÙÁ¦(¡­ð¥)
  • alpha-ketoglutarate
    ¾ËÆÄ-ÄÉÅä±Û·çŸ·¹ÀÌÆ®
  • alpha-l-iduronidase
    a-L-Iduronidase
  • alpha-lipoproteinemia
    ¾ËÆÄ-Áö¹æ´Ü¹éÇ÷Áõ
  • alpha-naphthyl acetate esterase
    ¾ËÆÄ-³ªÇÁÆ¿¾Æ¼¼Å×ÀÌÆ®¿¡½ºÅ×¶óÁ¦
  • alpha-naphthyl acetate esterase =ANAE
    ¾ËÆÄ¾Æ¼¼Å×ÀÌÆ®¿¡½ºÅ×¶óÁ¦
  • alpha-naphthyl butyrate esterase
    ¾ËÆÄ-³ªÇÁÆ¿ ºÎƼ·¹ÀÌÆ®¿¡½ºÅ×¶óÁ¦
  • alpha-naphthyl butyrate esterase =ANBE
    ¾ËÆÄºÎƼ·¹ÀÌÆ®¿¡½ºÅ×¶óÁ¦
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • gene fusion
    À¯ÀüÀÚ À¶ÇÕ(ë¶îîí­ë×ùê)
  • gene hypothesis
    À¯ÀüÀÚ ¼³(ë¶îîí­àã)
  • gene insertion
    À¯ÀüÀÚ »ðÀÔ(ë¶îîí­ßºìý)
  • gene library
    À¯ÀüÀÚ(ë¶îîí­) ¶óÀ̺귯¸®
  • gene linkage
    À¯ÀüÀÚ ¿¬°ü(ë¶îîí­Ö¤Î¼)
  • gene locus
    À¯ÀüÀÚ ºÎÀ§(ë¶îîí­Ý»êÈ)
  • gene mapping
    À¯ÀüÀÚ ÀÛµµ(ë¶îîí­íÂÓñ)
  • gene pair
    À¯ÀüÀÚ ½Ö(ë¶îîí­äª)
  • gene pool
    À¯ÀüÀÚ(ë¶îîí­) Ç®
  • gene product
    À¯ÀüÀÚ(ë¶îîí­) »ê¹°
  • gene reduncdancy
    À¯ÀüÀÚ Áߺ¹(ë¶îîí­ñìÜÜ)
  • gene reiteration
    À¯ÀüÀÚ Áߺ¹(ë¶îîí­ñìÜÜ)
  • gene repetition
    À¯ÀüÀÚ ¹Ýº¹(ë¶îîí­ÚãÜÖ)
  • gene splicing
    À¯ÀüÀÚ(ë¶îîí­) ½ºÇöóÀ̽Ì
  • gene substitution
    À¯ÀüÀÚ Ä¡È¯(ë¶îîí­öÇüµ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
LPF leukocytosis-promoting factor; leukopenia factor; lipopolysaccharide factor; localized plaque format...
MIF macrophage inhibitory factor; melanocyte[-stimulating hormone]-inhibiting factor; maximum inspirator...
MRF Markov random field; medical record file; melanocyte-[stimulating hormone]-releasing factor; mesence...
NF nafcillin; National Formulary; nephritic factor; neurofibromatosis; neurofilament; neutral fraction;...
RF radial fiber; radio frequency; receptive field; regurgitant fraction; Reitland-Franklin [unit]; rela...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
rHuTNF alpha Recombinant human tumor necrosis factor alpha
rhTNF-alpha Recombinant human tumour necrosis factor-alpha
rTNF alpha Recombinant tumor necrosis factor alpha
SDF1 alpha Stromal cell-derived factor 1 alpha
SDF-1 alpha Stromal derived factor-1 alpha
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • alpha-l-iduronidase
    a-L-Iduronidase
  • alpha-oxynaphthoic acid
    ¾ËÆÄ-¿Á½Ã³ªÇÁÅä»ê
    °áÁ¤¼ºÀÇ »ê,OHC10H6COOH.°ú°Å¿¡´Â ¹æºÎÁ¦, ¹æÃëÁ¦·Î »ç¿ëµÇ¾ú´Ù.
  • { alpha }`_{2 } ^{A } { gamma }`_{ 2} ^{F }

    ¶ó°í ±âÀçµÈ´Ù. Çì¸ð±Û·Îºó A(¼ºÀÎ Çì¸ð±Û·Îºó)´Â º¸Åë ¼ºÀÎÀÇ ´ëºÎºÐÀÌ µÇ¸ç,
    ¿ëÇ÷¼º
    Çì¸ð±Û·ÎºóÀÌ ÀûÇ÷±¸¿¡¼­ À¯¸®ÇÏ¿© Ç÷ÀåÁß¿¡ ³ªÅ¸³ª´Â ¼ºÁú.
  • myelinated A alpha mechanoreceptor
    À¯¼öÃÊ A-¾ËÆÄ ±â°è ¼ö¿ëü, À¯¼öÃÊ A-¾ËÆÄ ±â°è ¼ö¿ë±â
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
  • accessory food factor
    ¿µ¾ç º¸Á¶ ÀÎÀÚ
    F.G Ho
  • air kerma calibration factor
    °ø±â Ä¿¸¶ ÃøÁ¤ °è¼ö, ´«±Ý ¸ÂÃã °è¼ö
  • alveolar dilution factor
    ÆóÆ÷ Èñ¼® ÀÎÀÚ
  • angiogenesis factor
    Ç÷°ü Çü¼º ÀÎÀÚ
    ½Å»ý Ç÷°ü Áõ½ÄÀ» À¯µµÇÏ´Â ¹°Áú·Î¼­, Á¾¾çÀ̳ª ¸Á¸· °°Àº ½ÅÁø´ë»ç·®ÀÌ Å« Á¶Á÷¿¡¼­ ¹ß°ßµÈ´Ù. ÀÌ ÀÎÀÚ´Â »óóÀÇ °¡ÀåÀÚ¸®³ª Ç¥¸é¿¡ ÀÖ´Â Àú»ê¼Ò »óÅÂÀÇ ´ë½Ä¼¼Æ÷¿¡¼­ ºÐºñµÇ¸ç, »óó Ä¡À¯ °úÁ¤¿¡¼­ Ç÷°ü ÀçÇü¼ºÀ» À¯µµÇÑ´Ù.
  • anisotropy factor
    ºñµî¹æ¼º °è¼ö
  • antiangiogenesis factor
    Ç×Ç÷°ü»ý¼º ÀÎÀÚ
    Harvard ´ëÇп¡¼­ ¿¬±¸µÈ °ÍÀε¥ ¿¬°ñ¿¡´Â ¸ð¼¼Ç÷°üÀÌ Ä§ÅõµÇÁö ¾Ê´Â Çö»óÀ» °üÂûÇÏ°í ¾Ï Á¶Á÷¿¡ ¿¬°ñÁ¶Á÷¿¡¼­ À¯·¡µÈ antiangiogenesis factor¶ó´Â °ÍÀ» »ç¿ëÇÏ¿© ¾Ï Á¶Á÷ÀÇ ¼èÅ𸦠ÃÊ·¡ÇÏ¿´´Ù.
  • antihemophilic factor
    Ç×Ç÷¿ìº´ ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰 ÀÎÀÚ
  • antistiffness factor
    Ç×°­Á÷ ÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ¼º ³ªÆ®·ý ÀÌ´¢ ÀÎÀÚ
  • CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
    gene cloning <molecular biology> The insertion of a DNA sequence into a vector that can then be propagated in a host organism, generating a large number of copies of the sequence.
    (18 Nov 1997)
    gene cluster A set of closely related genes that code for the same or similar proteins and which are usuallygrouped together on the same chromosome.
    (09 Oct 1997)
    gene conversion <molecular biology> A phenomenon in which alleles are segregated in a 3:1 not 2:2 ratio in meiosis. May be a result of DNA polymerase switching templates and copying from the other homologous sequence or a result of mismatch repair (nucleotides being removed from one strand and replaced by repair synthesis using the other strand as template).
    (18 Nov 1997)
    gene deletion The total loss (or absence) of a gene. Gene deletion plays a role in birth defects and in the development of cancer.
    (12 Dec 1998)
    gene disorder Hereditary disorder caused by a mutant allele of a single gene (e.g., Duchenne muscular dystrophy, retinoblastoma, sickle cell disease).
    Compare polygenic disorders.
    (05 Mar 2000)
    gene disruption Use of both in vitro and in vivo recombination to substitute an easily selected mutant gene for a wild-type gene.
    (09 Oct 1997)
    gene divergence The difference (expressed as a percentage) in the nucleotide sequencesbetween two related genes that developed from the same ancestral gene.
    (09 Oct 1997)
    gene dosage <molecular biology> Number of copies of a particular gene locus in the genome, in most cases either one or two.
    (18 Nov 1997)
    gene dosage compensation The putative mechanism that adjusts the X-linked phenotypes of males and females to compensate for the haploid state in males and the diploid state in females. It is now largely ascribed to lyonization which compensates the mean of the dose but not its variance, which is greater in females.
    (05 Mar 2000)
    gene dosage effect In codominant alleles, the more or less linear relationship between the phenotypic value and the number of genes of one type substituted by another type.
    (05 Mar 2000)
    gene duplication <molecular biology> A class of DNA rearrangement that generates a supernumerary copy of a gene in the genome. This would allow each gene to evolve independently to produce distinct functions. Such a set of evolutionarily related genes can be called a gene family.
    (18 Nov 1997)
    gene, evolutionarily conserved A gene that has remained essentially unchanged throughout evolution. Conservation of a gene indicates that it is unique and essential. There is not an extra copy of that gene with which evolution can tinker. And changes in the gene are likely to be lethal.
    (12 Dec 1998)
    gene expression <molecular biology> The full use of the information in a gene via transcription and translation leading to production of a protein and hence the appearance of the phenotype determined by that gene. Gene expression is assumed to be controlled at various points in the sequence leading to protein synthesis and this control is thought to be the major determinant of cellular differentiation in eukaryotes.
    (18 Nov 1997)
    gene expression regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action at the level of transcription or translation. These processes include gene activation and genetic induction.
    (12 Dec 1998)
    gene expression regulation, archaeal Any of the processes by which cytoplasmic or intercellular factors influence the differential control of gene action in archaea.
    (12 Dec 1998)
    ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
    KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • Á¦Ç°¸í
      ¼ººÐ/ÇÔ·®
      ±¸ºÐ/º¸Çè±Þ¿©
    KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • Á¦Ç°¸í
      ¼ººÐ/ÇÔ·®
      ±¸ºÐ/º¸Çè±Þ¿©
    ¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    ¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
      ÇÑÀÚ
    ´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
      ÇÑÀÚ
    ´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ÄÚµå
      ¿µ¹®
      ÇѱÛ
    Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ÄÚµå
      ¿µ¹®
      ÇѱÛ
    °æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
      ¼³¸í
    CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
    MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
    Á¦Ç°¸í
    ÆÇ¸Å»ç
    º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
    ¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
    Á¦Ç°¸í
    ÆÇ¸Å»ç
    º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
    ¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
    KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
    ÅëÇÕ°Ë»ö ¿Ï·á